This ad will auto close in 10 seconds

Sun Pharma shares bounce back, up nearly 2% at close

Shares of Sun Pharmaceutical Wednesday recovered nearly 2 percent to close at Rs 967.15 on BSE a day after the stock took a severe beating following Daiichi Sankyo selling its entire 9 percent stake in the company for Rs 20,025 crore.

Sun Pharma shares bounce back, up 3% on bourses

Stocks of Sun Pharmaceutical made a comeback at the bourses Wednesday, rising nearly 3 percent, a day after Japanese drugmaker Daiichi Sankyo sold its entire stake of around 9 per cent in the company for Rs 20,025 crore.

Daiichi Sankyo exits Sun Pharma; ends 7 years of tumultuous ride in India

Daiichi Sankyo exits Sun Pharma; ends 7 years of tumultuous ride in India

The company, which had forayed into the growing Indian pharmaceutical market by buying a majority stake in Ranbaxy Laboratories in 2008 for Rs 22,000 crore, sold over 21 crore shares in Sun Pharma.

Sun Pharma shares tank 11% as Daiichi completes exit

Shares of Sun Pharmaceutical on Tuesday plunged nearly 11 percent after Japan's Daiichi Sankyo announced selling its entire holding in the Indian drug major for an estimated Rs 20,420 crore.

Sun Pharma slumps most in near six years on Daiichi's share sale

Shares of Sun Pharmaceutical Industries Ltd slumped as much as 10.9 percent on Tuesday, heading towards their biggest daily fall since June 2009 after Japan`s Daiichi Sankyo Co Ltd started selling its stake in the Indian drugmaker.

Daiichi files plea in HC to vacate stay on Sun-Ranbaxy merger

Daiichi Sankyo, owner of Ranbaxy Laboratories Limited, has filed a petition in Andhra Pradesh High Court requesting it to vacate the 'status quo' order it issued earlier on Sun Pharma-Ranbaxy merger process.

Sun Pharma shares gain 7%, up 2nd day post Ranbaxy deal

The scrip ended 6.91 percent up at Rs 627.80 on the BSE. During the day, it surged 8 percent to touch Rs 634.80. Ranbaxy stock rose 4.90 percent to Rs 467.

Govt to review FDI policy in pharma sector on Monday

Government will take up on Monday the issue of tightening FDI in existing pharmaceutical companies in the wake of concerns over multinationals taking over domestic drug makers.

Daiichi Sankyo's allegations false & baseless: Malvinder Singh

Ranbaxy rebutted the allegations saying they did not misrepresent any facts or falsify any data.

Ranbaxy shares dive over 9% after Daiichi says misled over probes

Following the weakness in the stock, the market value of the company slipped by Rs 1,527 crore to Rs 16,708 crore.

Ranbaxy, Daiichi Sankyo to collaborate in Brazil to expand biz

Drug major Ranbaxy Laboratories and its Japanese parent Daiichi Sankyo on Wednesday announced synergies in Brazil to expand their business in the Latin American nation.

Ranbaxy, Daiichi Sankyo to leverage synergies in Thailand

Both the companies intend to integrate their business operations in Thailand.

Daiichi Sankyo to sell Ranbaxy's products in Venezuela

Japanese pharma major Daiichi Sankyo will start selling Ranbaxy Laboratories products in Venezuela under their hybrid business model, the two companies said on Wednesday.